Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phellinus linteus mycelium extract
- Development stage
- Unknown
- Lead developer
- Hankook Shinyak
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Mesima (Phellinus linteus mycelium extract) is an approved immunomodulatory and immunostimulant drug developed by Hankook Shinyak in collaboration with the Korea Research Institute of Bioscience and Biotechnology (KRIBB). It is derived from the mycelium of the medicinal mushroom *Phellinus linteus* (known as Sang-Hwang in Korea) and contains the protein-bound polysaccharide PPLA (Protein Polysaccharide of Phellinus linteus Aoshima). Mesima is approved in South Korea as an adjuvant therapy to enhance immune function in patients undergoing chemotherapy following surgery for digestive system cancers (including gastric, esophageal, duodenal, colon, and rectal cancers) and liver cancer. It is also indicated for the treatment of metrorrhagia, leucorrhea, menstrual irregularity, and enterohemorrhage. Mesima acts as a biological response modifier, stimulating B-lymphocytes, activating macrophages, and modulating cytokine production (such as enhancing IFN-γ and IL-12) to boost host antitumor immunity and reduce chemotherapy-induced toxicity.
- Brand names
- MesimaMesima Cap.Mesima-Ex
- Other names
- P.P.L.A.PPLAPhellinus linteus mycelium-derived protein polysaccharideprotein polysaccharide PPLAprotein-bounded polysaccharide PPLA
02
Targets
ABCA1 (ATP-binding cassette transporter A1)ABCG1 (ATP-binding cassette sub-family G member 1)CDK2 (Cyclin-dependent kinase 2)CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)CLEC7A (Dectin-1)MAPK3 (Mitogen-activated protein kinase 1)GAB2IFNG (Interferon gamma)IL12 (Interleukin-12)MMP1 (Matrix metalloproteinase-1)PPARG (Peroxisome proliferator-activated receptor gamma)SYK (Spleen Tyrosine Kinase)TLR (Toll-like receptors)RK (Ribokinase)
Beyond the preview
Go deeper on Phellinus linteus mycelium extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phellinus linteus mycelium extract.